NASDAQ · Biotechnology

TYRA (TYRA) Stock

$30.85 -0.69% NASDAQ: TYRA Healthcare

Valuation

MetricValue
Price$30.85
Market Cap$1.83B
P/E Ratio-17.16
P/B Ratio7.92
P/S Ratio0.00
EPS (TTM)$-2.01
52-Week High$40.65
52-Week Low$8.98
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-46.33%
ROA-42.40%
ROCE-51.15%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.01
Current Ratio14.72

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-26.0M$-59.0M$-80.0M$-104.0M$-133.0M
Net Profit$-26.0M$-55.0M$-69.0M$-86.0M$-120.0M
EPS$-0.63$-1.23$-1.62$-1.51$-2.01
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$307.0M$266.0M$226.0M$364.0M$283.0M
Total Liabilities$5.0M$8.0M$22.0M$20.0M$23.0M
Cash$302.0M$251.0M$58.0M$92.0M$77.0M
Borrowings$1.0M$3.0M$6.0M$6.0M$6.0M

Latest News

Is Tyra Biosciences, Inc. (TYRA) Stock a Biotech Opportunity Ahead of Key SURF302 Trial Data? Insider Monkey · Jun 30, 2026 Non-muscle Invasive Bladder Cancer Market Dynamics to Shift During the Forecast Period (2026-2036) as Novel Targeted and Gene Therapies Enter Late-Stage Development | DelveInsight PR Newswire · Jun 23, 2026 Is Tyra Biosciences (TYRA) Too Reliant On Dabogratinib Amid Renewed SURF-302 Skepticism? Simply Wall St. · Jun 12, 2026 Tyra Biosciences' Weak Investor Sentiment Reflects Macro Pressures, Renewed SURF-302 Concerns, BofA Says MT Newswires · Jun 10, 2026 Wolfe Research Initiates Peer Perform rating on Tyra Biosciences, Inc. (TYRA) Insider Monkey · Jun 1, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-24.0M$-50.0M$-50.0M$-70.0M$-95.0M
Investing Cash Flow$-1.0M$-1.0M$-145.0M$-99.0M$72.0M
Financing Cash Flow$1.0M$0$0$2.0M$0
Net Cash Flow$287.0M$-51.0M$-193.0M$34.0M$-15.0M
Free Cash Flow$-24.0M$-51.0M$-51.0M$-70.0M$-95.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-5.10%
Quick Ratio20.49
Interest Coverage—
Return 1Y179.65%
Return 3Y92.79%
Return 5Y—

Ownership

Insiders Held2.86%
Institutions Held111.66%
Institutions Float Held114.95%
Institutional HolderSharesReport Date
RA Capital Management, L.P.12,198,6252026-03-31
FMR, LLC7,747,6482026-03-31
Nextech Invest, Ltd.4,055,8612026-03-31
Janus Henderson Group PLC3,890,5892026-03-31
Alta Partners Management Company, L.P. 3,823,4252026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
DAWNDay One Biopharmaceuticals, Inc. $21.53 +0.00% -20.70 $2.22B 0.00%
EYPT $12.41 +1.80% -4.34 $1.04B 0.00%
GERN $1.34 -4.29% 23.17 $859.64M 0.00%
KURA $9.57 +3.13% -2.90 $849.57M 0.00%
MRVI $6.90 +3.06% -4.48 $1.90B 0.00%

About TYRA

TYRA stock trades at $30.85 with a market capitalization of $1.83B. The stock is valued at a price-to-earnings (P/E) ratio of -17.16, price-to-book of 7.92, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $8.98 and $40.65, and currently trades 24.1% below its 52-week high.

On profitability, TYRA generates a return on equity (ROE) of -46.33%, return on capital employed of -51.15%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides